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IN FOCUS
Understanding the mysteries of iPS cells
Justin Brent Cohen* and Diane S. Krause
Yale Stem Cell Center, New Haven, Connecticut
The development of induced pluripo-
tent stem (iPS†) cells is one of the newest
and most exciting areas of stem cell re-
search.
Takahashi and Yamanaka, in a land-
mark paper in 2006 [1], were able to
demonstrate that cultured and fully differ-
entiated mouse fibroblasts could be trans-
formed into pluripotent embryonic-like
stem cells able to produce all three germ
layers in addition to chimeric animals. But
what made this finding even more astonish-
ing was that only four transcription factors
needed to be transduced for this transfor-
mation.These newly derived iPS cells have
tremendous promise because they lack the
typical ethical and immunological prob-
lems of other approaches. Ethically, no
human embryos would have to be used in
their creation, and immunologically, a pa-
tient’s own genetically identical cells could
be transplanted.The heretofore locked door
to truly regenerative medicine finally
seems to have found its key in iPS cells.
At StemCONN 2009, a Connecticut-
wide scientific symposium that took place
at the Omni Hotel in New Haven in March,
Konrad Hochedlinger of Massachusetts
General Hospital and Harvard Medical
School addressed the question of how
broadly the iPS conversion strategy can be
applied, i.e., whether this method of cellu-
lar reprogramming is specific only to cul-
tured mouse fibroblasts. These starting
cells are far removed genetically and envi-
ronmentally from the typical cells that re-
side in the body.
Hochedlinger presented data showing
that even terminally differentiated pancre-
atic cells were able to be reprogrammed
using the same four factors: c-myc, Klf4,
Oct4, and Sox2 [2]. Other cell types also
have been shown to be iPS compatible, in-
cluding lymphocytes [3], liver cells [4], in-
testinal cells [5], and neural progenitors [6],
suggesting that in vitro reprogramming
may be a universal process. However,
slight alterations in the combinations of
factors required for reprogramming can be
seen depending on the endogenous expres-
sion patterns of certain cell types. Specifi-
cally, c-myc, Klf4, and Sox2 are expressed
in multiple adult tissues, and their pattern
of expression can affect iPS creation. For
example, neural progenitor cells lack a
Sox2 transduction requirement because of
the already naturally high level of this tran-
scription factor in this cell type. However,
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and debatably the most important, determi-
nant of direct reprogramming.
These landmark findings led
Hochedlinger to propose that the stoichiom-
etry of each factor is critically significant in
the reprogramming process, since too much
of any one transgene appears to be toxic to
the cells, while insufficient amounts will not
lead to faithful iPS creation.
Hochedlinger explained that based on
the current understanding, iPS cells and em-
bryonic stem (ES) cells are similar, both
molecularly and functionally [7]. For exam-
ple, iPS cells show reactivation of pluripo-
tency genes, telomerase activity, and a silent
X chromosome in female cells, as well as
genome-wide transcriptional and epigenetic
patterns that are characteristic of ES cells.
Moreover, iPS cell chimeras give rise to off-
spring, indicating that these cells can con-
tribute to the germline.
But the comparison of iPS cells and ES
cells is not simple, because other studies
have shown defective differentiation and
commitment into mature cardiac myocytes
when using an iPS starting population vs. ES
cells. Furthermore, about one-third of iPS
chimeras succumb to tumors that are likely
related to the reactivation of retroviral trans-
genes and insertional mutagenesis, exposing
a critical technical problem associated with
the original methods of producing iPS cells:
Retroviruses or lentiviruses must be de-
ployed to stably integrate exogenous DNA
into the host cells’ genome. Unfortunately,
this integration frequently falls into onco-
gene or tumor suppressor loci, leading to
malignant transformation.Newer techniques
use non-integrating viruses, transiently
transfected adenoviruses, or even small mol-
ecule activators. These methods, which di-
minish the negative consequences of prior
techniques, are essential before any promis-
ing human treatment method could be con-
sidered.Yet the robustness and efficiency of
these methods remains to be proven.
Currently, most protocols demonstrate
efficiencies of only between 0.01 percent to
0.1 percent. Hochedlinger suggested that
much of this inefficiency arises from the
small probability that all four viral vectors
(each containing one of the necessary trans-
genes) infect one cell while still maintaining
a stable copy number and randomly insert-
ing into a “safe” genomic region. Without a
“safe” integration site, the viruses used to
create iPS cells could damage an endoge-
nous gene that is essential for the reacquisi-
tion of the pluripotent, self-renewing state.
In addition, it has been proposed that the low
efficiency is also dependent on the presence
of rare tissue-resident stem cells within the
starting population [7]. It is possible that this
stem cell population alone is responsible for
iPS creation, because a relatively immature
cell fate may mean that these cells are better
primed genetically for pluripotent repro-
gramming. Hochedlinger, however, was un-
convinced that adult stem cells are the
selective target population and instead fo-
cused on the observation that endodermal
derivatives are more amenable to repro-
gramming than cells of mesodermal origin.
Nonetheless, the question remains an open
one with ongoing work on both sides of the
debate yielding conflicting results as to the
need for a specific iPS cell of origin.
As work continues to understand the
mechanism and cellular requirements for re-
programming, it is certain that further exper-
imentation to optimize the induction of
pluripotency will lead to an efficient mech-
anism. iPS cell yields of much greater than
0.1 percent are necessary in order to func-
tionally repair the typical organ system com-
posed of millions of cells. Only with
improvements in these yields can true ther-
apeutic application of this cellular therapy
be realized.
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